We conducted a randomized controlled trial to determine whether empirical treatment of severe acute community-acquired gastroenteritis (four ftuid stools per day for >3 days) with ciproftoxacin reduces the duration of diarrhea and other symptoms and to determine what effect ciproftoxacin has on the duration of long-term fecal carriage of gastrointestinal pathogens. A total of 173 patients were recruited for the study and received either ciproftoxacin (500 mg b.i.d.) or placebo for 5 days, during which time they recorded the duration of diarrhea and other symptoms (fever, abdominal pain, vomiting, and myalgia). Fecal samples were collected before treatment and regularly after treatment to determine the duration of carriage of gastrointestinal pathogens. Antibiotic susceptibility tests were performed, and the minimum inhibitory concentrations (MICs) of ciproftoxacin were determined. A significant reduction in the duration of diarrhea and other symptoms was observed after treatment, regardless of whether a pathogen was detected (P = .0001). Treatment failure occurred in 3 of 81 patients in the ciproftoxacin group and 17 of 81 patients in the placebo group. Significant pathogens were detected in 87% of patients, 85.5% of whom had cleared the pathogen at the end of treatment with ciproftoxacin, as compared with 34% who received placebo. Six weeks after treatment, there was no difference between the two groups in terms of the pathogen carriage rate (12%). Treatment with ciproftoxacin did not prolong carriage. High-level resistance to ciproftoxacin (MIC, >32 mglL) was detected in three strains (4%) of Campylobaeter species.
supportive therapy. In the United Kingdom, Campylobacter species, followed by Salmonella species and Shigella species, are the most common causes of acute bacterial gastroenteritis. Antibiotic treatment of acute gastroenteritis has generally been discouraged because the disease is usually self-limiting, and often the patient is recovering by the time the microbiological diagnosis is made. Antibiotics are ineffective for viral infections, and the view has long been that antibiotics do not reduce the duration of symptoms of bacterial gastroenteritis [3] and may indeed prolong gastrointestinal carriage of the pathogen [4, 5] .
Ciprofloxacin, a fluoroquinolone, is active against all the recognized bacterial causes of gastroenteritis. It concentrates at high levels within the enteric mucosa, does not greatly affect the normal anaerobic bowel flora [6] , and penetrates effectively into macrophages [7] ; all of these characteristics make this agent an effective drug for treatment ofbacterial gastroenteritis. Ciprofloxacin has been effective in the treatment of enteric fever [8] [9] [10] , traveler's diarrhea [11, 12] , and acute diarrhea in patients admitted to the hospital [13] as well as those presenting to the hospital [14] . This drug has also been used with mixed success to clear gastrointestinal carriage of pathogens [15] [16] [17] [18] . Most cases of bacterial gastroenteritis are community acquired, and only a minority of patients require hospitalization. Therefore, we studied the efficacy of ciprofloxacin in the treatment of severe acute community-acquired gastroenteritis.
Methods
Patients over the age of 18 who were not pregnant and presented to their general practitioners with severe acute gastro-em 1996; 22 (June) enteritis were recruited for the study. Severe acute gastroenteritis was defined as diarrhea (more than four fluid stools per day) that had not abated in~3 days in an otherwise healthy person with at least one of the following symptoms: abdominal pain, fever, vomiting, myalgia, or headache. The severity of these symptoms and the need for parenteral rehydration were not used as inclusion criteria.
Patients were told that they would receive an active agent or placebo in addition to standard supportive therapy (fluids and no food until the return of appetite, followed by bland foods until the return of normal bowel habits). Antiperistaltic drugs were not recommended, but if they were prescribed by the general practitioner, they could be taken as required.
Patients recorded their own symptoms by completing a questionnaire on the date and time of the onset of illness, the last fluid stool, and the time it took (to the nearest half day) for the stool consistency and stool frequency to return to normaL The presence and duration of vomiting, abdominal pain, fever, myalgia, headache, and general malaise were noted. Many patients did not measure their temperatures; therefore, fever was merely defined as feeling hot, shivery, or sweaty. A record was made of underlying illnesses or medications, history of recent travel outside the United Kingdom, and adverse reactions to the treatment. The questionnaire was returned to the investigators after patients recovered.
Patients were randomized to receive placebo or ciprofloxacin (500 mg bj.d.). Treatment was blinded, and patients were given a numbered tablet container; the list of numbers and which tablets the patients had received was retained by the hospital pharmacy until the end of the study. Placebo and ciprofloxacin tablets were indistinguishable. Compliance was determined by asking patients if they had completed the course of treatment and by requesting return of the numbered tablet container with the questionnaire. Stool samples were collected on recruitment into the study; additional stool samples were requested 2-3 days after the 5-day course of treatment had been completed and again 6 weeks later. Additional stool samples were collected each week from patients in whom carriage of a pathogen persisted.
Patients infected with pathogens such as Giardia lamblia or Entamoeba histolytica, for which appropriate alternative therapy was available, were excluded from the triaL Patients in whom no pathogens were detected or who were infected with pathogens such as Cryptosporidium species, for which no satisfactory treatment exists, remained in the triaL Treatment failure was recorded for patients who had no decrease in the frequency or severity of diarrhea towards the end of the course of treatment or who continued to have severe abdominal pain. Some of these patients were offered alternative therapy at the discretion of their general practitioners; this therapy included ciprofloxacin for those with infections due to Salmonella species and Shigella species or erythromycin for those with infections due to Campylobacter species. In addition, supportive therapy (including parenteral rehydration in the hospital) was offered when clinically indicated. Patients who received additional therapy were not included in the analysis of the duration of illness or duration of gastrointestinal carriage of pathogens, but they were included in the comparison of treatment failures.
Stool samples were processed in the microbiology laboratory with use of routine methods. Samples were inoculated on deoxycholate citrate agar (DCA; bioMerieux, Basingstoke, England), on xylose-lysine-deoxycholate agar (XLD; bioMerieux), and in selenite broth and incubated aerobically at 37°C for 18-24 hours; they were also inoculated on campylobacter blood-free selective agar (Oxoid; Basingstoke) and incubated under microaerophilic conditions at 37°C. Microscopic examinations for ova, cysts, and parasites (including a phenol auramine stain for detection of Cryptosporidium species) was performed. Significant isolates were identified by means of routine methods. Campylobacter isolates were identified to the species level on the basis of their ability to hydrolyze hippurate.
Antibiotic susceptibility was determined by a disk diffusion method [18] Data were recorded in a file (Dbase IV, Borland, CA) by patient number. The data analyzed included age, sex, pathogen isolated, total duration of symptoms, duration of diarrhea after the start of treatment, duration of other symptoms after the start of treatment, presence of the pathogen immediately after discontinuation of treatment, and persistence of the pathogen 6 weeks after discontinuation of treatment. At the end of the study, a separate file containing the treatment coding was combined with the main clinical data file. The duration of diarrhea and other symptoms in the two groups was compared by the Wilcoxon two-sample test. Statistical comparison of treatment failure in the two groups was performed by means of the X 2 test.
Results
One hundred and seventy-three patients were recruited for the study. Eleven of these patients were excluded for the following reasons: one patient concurrently received other antibiotics, eight failed to comply with the therapeutic protocol, and two had diagnoses other than gastroenteritis (inflammatory bowel disease and giardiasis). Patients were not excluded for failure to provide any of the three stool samples, but those who did not provide the necessary sample were rigourously encouraged to do so.
Eighty-one patients could be evaluated in each arm of the triaL There were no statistical differences between the two groups of patients in terms of age, sex, history of travel, or figure 1 . Ciprofloxacin treatment reduced the duration of symptoms regardless of whether a pathogen was detected or whether its identity was determined (figure 2). For patients whose symptoms did not resolve,· treatment failure was recorded. There were three treatment failures in the ciprofloxacin group, compared with 17 in the placebo group (P < .001).
One patient in the ciprofloxacin group and four in the placebo group received alternative antimicrobial therapy after treatment failure was recorded. These patients were not included in the analysis of duration of infection and carriage.
At the end of the 5-day course of treatment, follow-up stool samples were obtained from 69 of 71 patients in the ciproflox- carriers. These patients were followed up by means of weekly examinations of stool samples. Carriage persisted for a mean of 10.3 weeks (range, 7-20 weeks) in the ciprofloxacin group and 11.5 weeks (range, 9-18 weeks) in the placebo group. There was no significant difference in the patterns of carriage rates among the subsets ofpatients infected with specific organisms (table 4) . In no case was a pathogen detected after discontinuation of therapy in patients who had had negative fecal microbiology on admission to the trial. For one patient who received ciprofloxacin, the pathogen was not detected at the end of treatment but was present 6 weeks later. This patient, who was subsequently found to have hairy-cell leukemia, developed septicemia and splenic abscess caused by Salmonella enteritidis 2 months after leukemia was diagnosed.
All but three isolates were susceptible to ciprofloxacin; these three isolates were Campylobacter species for which the MICs of ciprofloxacin were > 32 mg/L. Only one of these infections was acquired abroad (Majorca). Two of the patients received placebo and recovered without further treatment; the third received ciprofloxacin, and although the diarrhea resolved after 4 days, the patient continued to have severe abdominal pain, which was considered treatment failure. This patient was given erythromycin. The organism continued to be isolated from the patient's stool after ciprofloxacin therapy but was absent 6 weeks after treatment with erythromycin.
No demonstrable resistance developed during treatment. A susceptible strain of Campylobacter jejuni (MIC of ciprofloxacin, 0.125 mg/L) was detected in a pretreatment stool sample from one patient who was found to have a resistant Campylobacter strain (MIC of ciprofloxacin, >32 mg/L) at the end of treatment. However, the isolate recovered after treatment was identified as Campylobacter coli. Presumably, both strains were present before treatment, but only the susceptible one was detected.
The MICs of ciprofloxacin for species of Salmonella and Shigella were low (range, 0.006-0.094 mg/L) (figure 3). Only 9 (37.5%) of 24 isolates acquired abroad vs. 36 (92.3%) of39 isolates acquired in the United Kingdom were fully susceptible to all the antibiotics tested. Twenty-eight percent ofSalmonella and Shigella isolates were resistant to amoxicillin, 19% were resistant to trimethoprim, and 6.3% were resistant to chloramphenicol. Resistance to cefuroxime or gentamicin was not demonstrated. The MICs of ciprofloxacin for isolates of Campylobacter species were higher (range, 0.016->32 mg/L) (figure 3). Only 3 (4.2%) of 72 isolates were resistant to nalidixic acid and ciprofloxacin. Resistance to erythromycin was not demonstrated.
Ciprofloxacin therapy was well tolerated, with few reported adverse effects. Eight patients reported adverse effects; only two of these adverse effects could be attributed to ciprofloxacin and included an unpleasant taste and vaginal thrush. Other adverse effects reported in the ciprofloxacin group included "short temper," "muscle jumping," "swollen, painful second finger," and "felt sick," and those reported in the placebo group included "felt sick" and, surprisingly, "constipation."
Discussion
This study demonstrated that a 5-day course of therapy with oral ciprofloxacin reduces the duration of diarrhea and other symptoms in patients with severe acute community-acquired gastroenteritis. A reduction in the duration of symptoms was observed regardless of whether a pathogen was detected. Most gastroenteritis is short-lived, self-limiting, and clinically mild. Such cases clearly do not require antibiotic therapy. Gastroenteritis is generally perceived as a self-limiting illness, and patients tend not to consult a physician unless the illness persists.
It is likely that the patients in this trial represented the moresevere end of the spectrum ofcommunity-acquired gastroenteritis. On average, they had been unwell for just over 4 days before seeking the help of a physician, and therefore their illnesses were unlikely to have been of viral etiology. The relatively late presentation of these patients makes a bacterial etiology more likely and explains the high rate (87%) of detection of gastrointestinal pathogens in the trial. Such patients are the ones who will benefit from empirical therapy.
Bacterial gastroenteritis in healthy persons is uncomfortable and disrupts their life. The average duration of illness in untreated patients in this study was -I week; therefore, if treatment reduces symptoms by a few days, it is worthwhile, particularly when it is safe and well tolerated. Gastroenteritis results in considerable morbidity, some mortality, and extensive costs in terms of/oss of wages and reduced productivity [2, 16] ; thus, an effective empirical treatment would be helpful. The general practitioner rarely has the luxury of knowing the etiologic agent when faced with a sick patient. Antibiotic treatment of gastroenteritis was previously discouraged because of its poor efficacy in patients with this condition [3] ; however, with the advent of the quinolones, this has changed.
Considerable experience with the quinolones in the treatment of gastrointestinal infection has been amassed worldwide, and most investigators have found the quinolones to be effective. Many of the studies have examined patients who have been admitted to the hospital [13] or who are in the hospital for treatment of specific infections such as shigellosis [20] . These studies have shown that therapy with the quinolones reduces the duration of symptoms. Empirical treatment of communityacquired diarrhea with ciprofloxacin in urban American adults showed that a 5-day course was more effective in reducing the duration of diarrhea than was therapy with co-trimoxazole (14] . In a multinational study conducted in Latin America and Italy, norfloxacin was found to be more effective than co-trirnoxazole (21] , and the cure rate was higher when the patient's stool sample contained leukocytes. Ciprofloxacin has been used successfully to treat typhoid [8, 10] and traveler's diarrhea (11,12J. If ciprofloxacin is to be administered empirically for gastroenteritis, who should receive it? Patients with proven bacterial gastroenteritis have a more-severe illness than do those from whom no pathogens are recovered [14] . Ciprofloxacin therapy should be reserved for adults who have unremitting diarrhea (more than four fluid stools per day) for> 3 days and who have Table 4 . Eradication ofpathogens among patients with severe acute gastroenteritis who received ciprotloxacin or placebo.
* Follow-up stool samples were obtained from 69 patients in the ciprofloxacin group and 67 in the placebo group.
t Final follow-up stool samples were obtained from 67 patients in the ciprofloxacin group and 65 in the placebo group.
had at least one of the following symptoms: fever (temperature, >38°C), vomiting, abdominal pain, or myalgia. The drug should be used as a adjunct to appropriate supportive therapy, particularly fluid replacement. A stool sample should always be collected before the initiation oftreatment so that the diagnosis can be confirmed, epidemiological information can be provided, and other treatable infections such as giardiasis or amebiasis can be excluded.
In the present study, ciprofloxacin was effective even in those patients from whom a pathogen was not recovered. The negative microbiological results could be explained in one of several ways: the laboratory failed to detect the pathogen, the patient was infected by a susceptible pathogen not routinely sought (e.g., a pathogenic strain of Escherichia coli or Yersinia species), or the patient was infected by a susceptible but as yet unrecognized pathogen.
The rate of pathogen eradication immediately after treatment was significantly higher in the ciprofloxacin group. The present study did not address the problem of microbiological relapse in the short term, which is of little significance to the patient providing symptoms have abated. Six weeks after treatment, there was no difference between the two groups in terms of the carriage rates. Follow-up of the persistent carriers did not demonstrate any difference between the groups in duration of carriage; thus, ciprofloxacin did not prolong pathogen carriage, as is widely believed to be the case following treatment with other antibiotics [6] . Ciprofloxacin therapy has been somewhat successful in eradicating carriage in symptomatic and asymptomatic excreters in a number of nosocomial outbreaks [6] . Indeed, during an outbreak in our own hospital, ciprofloxacin therapy eliminated carriage of S. enteritidis in asymptomatic catering staff; no relapse was observed up to 6 weeks after therapy [18] .
It is therefore surprising that two studies have reported unacceptable rates of microbiological relapse. In the first study, ciprofloxacin was used to eliminate fecal carriage ofSalmonella java in health care workers [16] . Treatment was started 9 days after the onset of illness, by which time most patients had no symptoms. The pathogen was rapidly cleared after therapy was begun. However, 2-3 weeks after treatment was discontinued, bacteriologic relapse was documented for four of seven patients.
Possible explanations for this relapse may be the late initiation of treatment or the pathogenicity of the Salmonella strain. In an open study, norfloxacin therapy cleared Salmonella typhimurium in 21 of 23 patients on the last day of a 7-day course; however, 10 of the patients had a subsequent bacteriologic relapse [17] . In neither of these studies did the quinolone unequivocally prolong carriage, nor was relapse associated with resistance of the pathogen. Since the pathogen was eventually eradicated naturally, the significance of its persistence in terms of public health is negligible, providing the patient practices good personal hygiene.
Ciprofloxacin has been shown in vitro to have a high degree of activity against a wide range of gastrointestinal pathogens from a variety of geographic locations [22] . The majority of the pathogens in the present study were susceptible to ciprotloxacin. No resistance to ciprofloxacin was detected among species of Salmonella and Shigella. Resistance to other antibiotics was more common in these organisms if the infecti(lfi had been acquired outside the United Kingdom; resistance to amoxicillin and trimethoprim was most common. However, two of the three ciprofloxacin-resistant were acquired in the United Kingdom, and both were highly resistant to the drug; the MICs of ciprofloxacin for these organisms were >32 mgIL. It has been shown that such high-level resistance to quinolones in other organisms emerges after prolonged exposure to the agent [23] . In the case of Campylobacter species, selective pressure is likely to have been due to antibiotic use in the agricultural setting [24] , although the development of high-level resistance has occurred during treatment of gastroenteritis [25] . The use of quinolones in animal husbandry is of concern. There is no evidence that these drugs reduce the pathogen load in raw meat products, and resistance to quinolones could emerge in other organisms that enter the food chain, limiting the usefulness of these agents in the treatment of human infections.
The question remains as to whether the reduction ('"2 days) in duration of symptoms warrants the recommendation that otherwise healthy patients with severe gastroenteritis be treated empirically with ciprofloxacin. Both medically and socioeconomically, such a reduction in the duration of symptoms is likely to be worthwhile. Further work is required to establish the true economic impact. It is also possible that a shorter course of ciprofloxacin therapy would be as effective, as has been demonstrated among patients with traveler's diarrhea [12] .
